ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,049 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 851-875 of 1,000 matching filings.

Per page
25
Current page
35
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jun 2020
Reporting date
01 Jun 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
01 Jun 2020
Reporting date
01 Jun 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC

Filing date
01 Jun 2020
Reporting date
01 Jun 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE

Filing date
01 Jun 2020
Reporting date
01 Jun 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2-

Filing date
29 May 2020
Reporting date
29 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE

Filing date
29 May 2020
Reporting date
29 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM

Filing date
29 May 2020
Reporting date
29 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
26 May 2020
Reporting date
26 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER

Filing date
22 May 2020
Reporting date
22 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST

Filing date
21 May 2020
Reporting date
21 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT

Filing date
20 May 2020
Reporting date
20 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER

Filing date
18 May 2020
Reporting date
18 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD

Filing date
18 May 2020
Reporting date
18 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET

Filing date
11 May 2020
Reporting date
11 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM

Filing date
11 May 2020
Reporting date
11 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F

Filing date
11 May 2020
Reporting date
11 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H

Filing date
06 May 2020
Reporting date
06 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 May 2020
Reporting date
01 May 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

RESULT OF AGM

Filing date
29 Apr 2020
Reporting date
29 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZN: FIRST-QUARTER 2020 RESULTS

Filing date
29 Apr 2020
Reporting date
29 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B

Filing date
24 Apr 2020
Reporting date
24 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING

Filing date
17 Apr 2020
Reporting date
17 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT

Filing date
14 Apr 2020
Reporting date
14 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC

Filing date
14 Apr 2020
Reporting date
14 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED

Filing date
02 Apr 2020
Reporting date
02 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .